- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01634269
Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis
Medtronic MDT-2111 CoreValve Japan 23mm Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kanagawa
-
Kamakura, Kanagawa, Japan
- Shonan Kamakura General Hospital
-
-
Osaka
-
Suita, Osaka, Japan
- Osaka University Hospital
-
Suita, Osaka, Japan
- National Cerebral and Cardiovascular Center
-
-
Saitama
-
Hidaka, Saitama, Japan
- Saitama Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must have co-morbidities such that one cardiologist and one cardiac surgeon agree that medical factors preclude operation, based on a conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement.
Subject has senile degenerative aortic valve stenosis with:
mean gradient > 40 mmHg or jet velocity greater than 4.0 m/s by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization (either resting or dobutamine stress), AND an initial aortic valve area of ≤ 0.8 cm² (or aortic valve area index ≤ 0.5 cm²/m²) by resting echocardiogram.
- Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class Class III or greater. If screening committee agrees the eligibility of a patient with class II , based on medical factors, he/she can be enrolled.
- Patient has been informed of the nature of the trial and has signed an Informed Consent Form.
- Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.
Exclusion Criteria:
- Evidence of an acute myocardial infarction ≤ 30 days prior to the intended treatment.
- Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the procedure.
Blood dyscrasias as defined:
- Leukopenia (WBC count < 1,000 cells/mm³)
- Thrombocytopenia (platelet count <50,000 cells/mm³)
- History of bleeding diathesis or coagulopathy
- Hypercoagulable states
- Untreated clinically significant coronary artery disease requiring revascularization.
- Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
- Need for emergency surgery for any reason.
- Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% as measured by resting echocardiogram.
- Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack(TIA).
- End stage renal disease requiring chronic dialysis.
- GI bleeding within the past 3 months.
A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:
- Aspirin
- Ticlopidine
- Heparin
- Contrast media
- Nitinol (titanium and nickel alloy)
- Ongoing sepsis, including active endocarditis.
- Subject refuses a blood transfusion.
- Life expectancy < 12 months due to associated non-cardiac co-morbid conditions.
- Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent.
- Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
- Currently participating in an investigational drug or another device trial. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- Symptomatic carotid or vertebral artery disease.
- Native aortic annulus size < 18 mm or > 20 mm per the screening diagnostic imaging.
- Pre-existing prosthetic heart valve in any position.
- Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation).
- Mitral regurgitation (moderate to severe) or severe tricuspid regurgitation.
- Moderate to severe mitral stenosis.
- Hypertrophic obstructive cardiomyopathy.
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
- Severe basal septal hypertrophy with an outflow gradient.
- Ascending aorta diameter > 34 mm
- Congenital bicuspid or unicuspid valve verified by echocardiography.
For patients with native coronary artery dependent circulation:
- Sinus of valsalva width < 25 mm OR
- Height of the left or right coronary sinus of valsalva (to the tubular aorta) < 15mm.
Femoral or iliac artery of the first choice corresponding to any one of the following:
- Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70°.
- Vessel diameter of femoral or iliac artery is less than 6 mm.
- Aorta has severe calcification, excess tortuosity or severe atherosclerosis.
- Transarterial access not able to accommodate an 18Fr sheath.
Subclavian artery of the second choice corresponding to any one of the following:
- Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70° (in the case of left subclavian artery) and 30° (in the case of right subclavian artery).
- Vessel diameter of subclavian artery is less than 6 mm.
- Transarterial access not able to accommodate an 18Fr sheath.
Direct Aortic Artery as third line choice of access. Patients are excluded from Direct Aortic access if:
- Access site is less than 6 cm from the aortic valve basal plane
- Access site has calcification or porcelain aorta
- Access site and delivery trajectory contain RIMA or patent RIMA graft
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MDT-2111 TAVI 23 mm
Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
|
Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA).
Time Frame: baseline and 6 months
|
The primary endpoint is a composite of functional effectiveness as measured by improvement of at least 1 NYHA class from baseline to 6 months and anatomical effectiveness as measured by Effective Orifice Area (EOA) ≥1.0 cm² at 6 months.
|
baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New York Heart Classification (NYHA) Over Time
Time Frame: 30 days
|
NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity. Class II: Subjects with cardiac disease resulting in slight limitation of physical activity. Class III: Subjects with cardiac disease resulting in marked limitation of physical activity. Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. |
30 days
|
New York Heart Classification (NYHA) Over Time
Time Frame: 6 months
|
NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity. Class II: Subjects with cardiac disease resulting in slight limitation of physical activity. Class III: Subjects with cardiac disease resulting in marked limitation of physical activity. Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. |
6 months
|
New York Heart Classification (NYHA) Over Time
Time Frame: 12 months
|
NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity. Class II: Subjects with cardiac disease resulting in slight limitation of physical activity. Class III: Subjects with cardiac disease resulting in marked limitation of physical activity. Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. |
12 months
|
New York Heart Classification (NYHA) Over Time
Time Frame: 24 months
|
NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity. Class II: Subjects with cardiac disease resulting in slight limitation of physical activity. Class III: Subjects with cardiac disease resulting in marked limitation of physical activity. Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. |
24 months
|
Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)
Time Frame: 0 day to 30 days
|
MACCE is defined as a composite of:
|
0 day to 30 days
|
Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)
Time Frame: 0 day to 6 months
|
MACCE is defined as a composite of:
|
0 day to 6 months
|
Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)
Time Frame: 0 day to 12 months
|
MACCE is defined as a composite of:
|
0 day to 12 months
|
Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)
Time Frame: 0 day to 24 months
|
MACCE is defined as a composite of:
|
0 day to 24 months
|
Device Success as Defined in the Description.
Time Frame: after procedure or discharge
|
The following components must be satisfied for device success:
|
after procedure or discharge
|
Procedural Success, Defined as Device Success and Absence of In-hospital MACCE
Time Frame: from admission for procedure to discharge
|
Procedural success is defined as device success and absence of in-hospital MACCE.
|
from admission for procedure to discharge
|
Echocardiographic Assessment of Prosthetic Valve Performance - Mean Gradient
Time Frame: 30 days
|
30 days
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Mean Gradient
Time Frame: 6 months
|
6 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Mean Gradient
Time Frame: 12 months
|
12 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Mean Gradient
Time Frame: 24 months
|
24 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
Time Frame: 30 days
|
30 days
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
Time Frame: 6 months
|
6 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
Time Frame: 12 months
|
12 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
Time Frame: 24 months
|
24 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Left Ventricular Ejection Fraction (LVEF)
Time Frame: 30 days
|
30 days
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Left Ventricular Ejection Fraction (LVEF)
Time Frame: 6 months
|
6 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Left Ventricular Ejection Fraction (LVEF)
Time Frame: 12 months
|
12 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Left Ventricular Ejection Fraction (LVEF)
Time Frame: 24 months
|
24 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
Time Frame: 30 days
|
30 days
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
Time Frame: 6 months
|
6 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
Time Frame: 12 months
|
12 months
|
|
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
Time Frame: 24 months
|
24 months
|
|
Repeat Hospitalization
Time Frame: 0 day to 30 days
|
0 day to 30 days
|
|
Repeat Hospitalization
Time Frame: 0 day to 6 months
|
0 day to 6 months
|
|
Repeat Hospitalization
Time Frame: 0 day to 12 months
|
0 day to 12 months
|
|
Repeat Hospitalization
Time Frame: 0 day to 24 months
|
0 day to 24 months
|
|
Valve-related Deaths
Time Frame: 0 day to 30 days
|
0 day to 30 days
|
|
Valve-related Deaths
Time Frame: 0 day to 6 months
|
0 day to 6 months
|
|
Valve-related Deaths
Time Frame: 0 day to 12 months
|
0 day to 12 months
|
|
Valve-related Deaths
Time Frame: 0 day to 24 months
|
0 day to 24 months
|
|
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
Time Frame: Baseline to 30 days
|
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status.
The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population.
The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score.
Norm-based score is then derived as fifty plus 10 times of the z-score.
A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
|
Baseline to 30 days
|
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
Time Frame: Baseline to 6 months
|
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status.
The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population.
The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score.
Norm-based score is then derived as fifty plus 10 times of the z-score.
A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
|
Baseline to 6 months
|
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
Time Frame: Baseline to 12 months
|
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status.
The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population.
The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score.
Norm-based score is then derived as fifty plus 10 times of the z-score.
A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
|
Baseline to 12 months
|
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
Time Frame: Baseline to 24 months
|
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status.
The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population.
The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score.
Norm-based score is then derived as fifty plus 10 times of the z-score.
A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
|
Baseline to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yoshi Sawa, Professor, Osaka University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDT-2111 23 mm trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Hospices Civils de LyonRecruiting
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Edwards LifesciencesActive, not recruitingHeart Failure | Aortic Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral StenosisUnited States, Canada, Poland
Clinical Trials on MDT-2111 TAVI 23 mm
-
Medtronic CardiovascularCompletedAortic Valve StenosisJapan
-
Institut für Pharmakologie und Präventive MedizinEdwards LifesciencesCompletedAortic Valve StenosisAustria, Canada, France, Germany, Italy, Spain, United Kingdom